How have NVIV shares performed in 2023?

InVivo Therapeutics' stock was trading at $2.35 at the beginning of the year. Since then, NVIV shares have decreased by 68.9% and is now trading at $0.73. View the best growth stocks for 2023 here .

Are investors shorting InVivo Therapeutics?

InVivo Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,000 shares, a drop of 88.2% from the October 31st total of 8,500 shares. Based on an average trading volume of 12,800 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company's stock are sold short. View InVivo Therapeutics' Short Interest .

When is InVivo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024. View our NVIV earnings forecast .

How were InVivo Therapeutics' earnings last quarter?

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) released its earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.87) earnings per share for the quarter.

When did InVivo Therapeutics' stock split?

InVivo Therapeutics shares reverse split before market open on Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of InVivo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Sciences (AVXL) , Gilead Sciences (GILD) , iShares Preferred and Income Securities ETF (PFF) , Verastem (VSTM) , Flexion Therapeutics (FLXN) , Inovio Pharmaceuticals (INO) , Apollo Investment (AINV) , IVERIC bio (OPHT) , OPKO Health (OPK) and Cardiff Oncology (TROV) .

How do I buy shares of InVivo Therapeutics?

Shares of NVIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

InVivo Therapeutics Stock Price, News & Analysis (NASDAQ:NVIV)

$0.73

+0.07 (+10.61%)

(As of 12/1/2023 ET)

Compare

Today's Range: $0.67
▼
$0.74
50-Day Range: $0.60
▼
$1.19
52-Week Range: $0.60
▼
$2.80

Volume: 27,449 shs
Average Volume: 48,279 shs
Market Capitalization: $2.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About InVivo Therapeutics Stock (NASDAQ:NVIV)

InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

NVIV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NVIV Stock News Headlines

December 2, 2023 | americanbankingnews.com

InVivo Therapeutics (NASDAQ:NVIV) Research Coverage Started at StockNews.com

November 24, 2023 | americanbankingnews.com

InVivo Therapeutics (NASDAQ:NVIV) Receives New Coverage from Analysts at StockNews.com

December 2, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 10, 2023 | morningstar.com

InVivo Therapeutics Holdings Corp NVIV

June 22, 2023 | marketwatch.com

Spinal Cord Trauma Treatment Market Analysis: Examining Trends and Forecasting Revenue Growth with an estimated CAGR 6.2% from 2023-2030

May 1, 2023 | benzinga.com

Ring Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate Strategy

March 17, 2023 | finance.yahoo.com

Why InVivo Therapeutics Shares Are Plunging Today

March 10, 2023 | msn.com

InVivo seeks longer-term control in Casino-Teract retail tie-up

December 2, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

March 10, 2023 | msn.com

Why Barnes & Noble Education Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket

March 10, 2023 | msn.com

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.66%

March 9, 2023 | msn.com

Why JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

March 9, 2023 | markets.businessinsider.com

InVivo : INSPIRE 2.0 Study In Acute Spinal Cord Injury Fails To Meet Primary Endpoint

March 9, 2023 | msn.com

InVivo to evaluate strategic options as trial for spinal injury device fails

March 9, 2023 | marketwatch.com

InVivo Therapeutics Shares Hit 52-Week Low After Study Misses Primary Endpoint

March 9, 2023 | marketwatch.com

InVivo Therapeutics Study for Neuro-Spinal Scaffold Misses Primary Endpoint

March 9, 2023 | finance.yahoo.com

InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury

January 11, 2023 | benzinga.com

InVivo Therapeutics Hldg Stock (NASDAQ:NVIV), Quotes and News Summary

October 11, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

October 10, 2022 | marketwatch.com

InVivo Therapeutics Shares Continue Friday's Fall, Hit All-Time Intraday Low

October 7, 2022 | seekingalpha.com

InVivo Therapeutics dips 24% on $9M direct and private placement offerings

October 7, 2022 | marketwatch.com

InVivo Therapeutics Stock Drops on $9 Million Offering

October 7, 2022 | investorplace.com

Why Is InVivo Therapeutics (NVIV) Stock Down 34% Today?

October 7, 2022 | finance.yahoo.com

InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

September 9, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference

August 28, 2022 | uk.finance.yahoo.com

InVivo Therapeutics Holdings Corp. (NVIV)

July 13, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel

See More Headlines

Receive NVIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/14/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NVIV
CUSIP: N/A
CIK: 1292519
Web: www.invivotherapeutics.com
Phone: (617) 863-5500
Fax: N/A
Employees: 6
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,490,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -75.04%
Return on Assets: -65.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.30
Quick Ratio: 14.30

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.87 per share
Price / Book: 0.25

Miscellaneous

Outstanding Shares: 3,110,000
Free Float: 3,085,000
Market Cap: $2.27 million
Optionable: Not Optionable
Beta: 0.86

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Richard M. Toselli (Age 65)
President, CEO, Chief Medical Officer & Director
Comp: $825.2k
Mr. Richard C. Christopher (Age 53)
CFO & Treasurer
Comp: $537.82k
Ms. Heather M. Hamel J.D. (Age 33)
Chief Legal Officer & General Counsel
Comp: $446.96k
Dr. Robert S. Langer Jr. (Age 74)
Ph.D., Co-Founder & Member of Scientific Advisory Board
Dr. Joseph Philip Vacanti M.D. (Age 74)
Co-Founder

Key Competitors

View All Competitors

NVIV Stock Analysis - Frequently Asked Questions

How have NVIV shares performed in 2023?: InVivo Therapeutics' stock was trading at $2.35 at the beginning of the year. Since then, NVIV shares have decreased by 68.9% and is now trading at $0.73.
View the best growth stocks for 2023 here.
Are investors shorting InVivo Therapeutics?: InVivo Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,000 shares, a drop of 88.2% from the October 31st total of 8,500 shares. Based on an average trading volume of 12,800 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company's stock are sold short.
View InVivo Therapeutics' Short Interest.
When is InVivo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024.
View our NVIV earnings forecast.
How were InVivo Therapeutics' earnings last quarter?: InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) released its earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.87) earnings per share for the quarter.

When did InVivo Therapeutics' stock split?: InVivo Therapeutics shares reverse split before market open on Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of InVivo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares Preferred and Income Securities ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), Apollo Investment (AINV), IVERIC bio (OPHT), OPKO Health (OPK) and Cardiff Oncology (TROV).
How do I buy shares of InVivo Therapeutics?: Shares of NVIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NVIV) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

InVivo Therapeutics Stock Price, News & Analysis (NASDAQ:NVIV)

About InVivo Therapeutics Stock (NASDAQ:NVIV)

NVIV Stock Price History

NVIV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NVIV Stock Analysis - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info